Changes in the treatment landscape of metastatic hormone‐sensitive prostate cancer following approval of upfront androgen receptor signaling inhibitors: A multicenter study

Abstract

Initial treatment with ARSIs in combination with ADT resulted in a longer time to CRPC and longer PFS2 compared to CAB. Although CAB and ADT alone were associated with fewer adverse events, ARSIs with ADT should be considered a first-line treatment option given its superior oncological outcomes.